ADC Therapeutics' IFRS loss for 6 months of 2020 amounted to $170,033 mln, a 3-fold increase from $49,858 mln in the previous year. The company did not receive any revenue in the reporting period. A year earlier, it was $2.34 mln.
ADC Therapeutics' IFRS loss for 6 months of 2020 amounted to $170,033 mln, a 3-fold increase from $49,858 mln in the previous year. The company did not receive any revenue in the reporting period. A year earlier, it was $2.34 mln. 
ir.adctherapeutics.com
English (US) 